Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Cisplatin Nephrotoxicity in Bladder Cancer
NCT06215976Phase 4Recruiting
- Sponsor
- Cairo University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin in cisplatin-induced nephrotoxicity (CIN) (2 arms), sponsored by Cairo University. Primary endpoints: Serum Creatinine at 12 weeks, Human Neutrophil Gelatinase-Associated Lipocalin at 12 weeks and 2 more. Started Jun 2023; status: recruiting.
02
Drugs
metformin
03
Conditions
cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT06215976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215976.